#1 Clinical Trials Search in Europe

Dabrafenib Mesylate

This article summarizes several clinical trials investigating the use of dabrafenib mesylate, often in combination with other drugs, for treating various types of cancer. Dabrafenib mesylate is a targeted therapy that inhibits the BRAF protein, which is involved in cell growth and division. These trials aim to evaluate the safety and effectiveness of dabrafenib-based treatments for cancers with specific genetic mutations, particularly BRAF mutations.

Table of Contents

What is Dabrafenib Mesylate?

Dabrafenib Mesylate, also known by its brand name Tafinlar, is an anti-cancer medication used to treat certain types of cancer[1]. It belongs to a class of drugs called BRAF inhibitors, which target a specific genetic mutation found in some cancers[2]. This medication is also known by other names, including:

  • Dabrafenib Methanesulfonate
  • GSK2118436 Methane Sulfonate Salt
  • GSK2118436B
These alternative names may be used in medical literature or by healthcare professionals, but they all refer to the same medication[3].

How Does Dabrafenib Mesylate Work?

Dabrafenib Mesylate works by targeting a specific protein called BRAF, which is involved in cell growth and division. In some cancers, the BRAF protein is altered due to a genetic mutation called BRAF V600. This mutation causes the BRAF protein to be overactive, leading to uncontrolled cell growth and cancer[2].

By blocking the activity of the mutated BRAF protein, Dabrafenib Mesylate helps to slow down or stop the growth of cancer cells. This targeted approach allows the medication to specifically attack cancer cells while potentially causing less harm to healthy cells[1].

What Conditions Does Dabrafenib Mesylate Treat?

Dabrafenib Mesylate is primarily used to treat cancers that have a BRAF V600 mutation. Some of the conditions it may be used to treat include:

  • Melanoma: A type of skin cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable)[4]
  • Non-small cell lung cancer: A type of lung cancer with the BRAF V600E mutation[1]
  • Anaplastic thyroid cancer: An aggressive form of thyroid cancer[5]
  • Erdheim-Chester Disease: A rare blood disorder that can affect multiple organs[2]
  • Certain types of brain tumors: Such as high-grade gliomas in children and young adults[6]
It’s important to note that Dabrafenib Mesylate is only effective in cancers that have the specific BRAF V600 mutation. Before prescribing this medication, your doctor will perform genetic testing on your cancer cells to determine if you have this mutation[1].

Combination Therapy with Trametinib

Dabrafenib Mesylate is often used in combination with another medication called Trametinib. Trametinib is a MEK inhibitor, which targets another protein in the same cellular pathway as BRAF. Using these two medications together can be more effective than using Dabrafenib alone[1].

The combination of Dabrafenib and Trametinib has shown promising results in clinical trials, particularly for treating melanoma. It may help to:

  • Improve the chances of shrinking tumors
  • Slow down the progression of cancer
  • Potentially extend overall survival in some patients
Your doctor will determine if combination therapy is appropriate for your specific situation[4].

How is Dabrafenib Mesylate Administered?

Dabrafenib Mesylate is typically taken orally (by mouth) in the form of capsules. The usual dosage is twice daily, but your doctor will determine the specific dose that’s right for you. It’s important to take the medication exactly as prescribed[1].

In some clinical trials, different dosing schedules are being studied. For example, some researchers are investigating whether taking breaks from the medication (called intermittent dosing) might be beneficial. However, you should not change your dosing schedule without consulting your doctor[7].

Potential Side Effects

Like all medications, Dabrafenib Mesylate can cause side effects. Some common side effects may include:

  • Fever
  • Fatigue
  • Skin rash
  • Joint pain
  • Headache
More serious side effects can occur, but they are less common. These may include new skin cancers, eye problems, or heart problems. It’s important to discuss all potential side effects with your healthcare provider and report any new or worsening symptoms promptly[4].

Ongoing Clinical Trials

Researchers continue to study Dabrafenib Mesylate to better understand its effects and explore new ways to use it. Some ongoing clinical trials are investigating:

  • The use of Dabrafenib in combination with other medications[8]
  • Different dosing schedules to potentially improve effectiveness or reduce side effects[7]
  • The effectiveness of Dabrafenib in treating other types of cancers or in different stages of disease[6]
If you’re interested in participating in a clinical trial, discuss this option with your healthcare provider. They can help determine if any ongoing trials might be appropriate for your situation.

Trial Focus Key Drugs Cancer Types Main Objectives
Combination therapy Dabrafenib, Trametinib Melanoma, Erdheim-Chester Disease, High-grade glioma Evaluate safety, efficacy, survival rates
Dosing strategies Dabrafenib, Trametinib BRAF V600 mutant melanoma Compare continuous vs intermittent dosing
Triple combination Dabrafenib, Trametinib, Hydroxychloroquine BRAF V600 mutant melanoma Assess if adding hydroxychloroquine improves outcomes
Sequencing therapies Dabrafenib, Trametinib, Ipilimumab, Nivolumab BRAF V600 mutant melanoma Compare different treatment sequences
Rare diseases Dabrafenib, Trametinib Erdheim-Chester Disease Evaluate efficacy in rare BRAF-mutant condition

FAQ

  • What types of cancer are being studied with dabrafenib mesylate? The clinical trials are studying dabrafenib mesylate in various cancers including melanoma, thyroid cancer, high-grade glioma, and Erdheim-Chester Disease. Most trials focus on cancers with BRAF V600 mutations.
  • What other drugs is dabrafenib mesylate often combined with in these trials? Dabrafenib mesylate is frequently combined with trametinib, another targeted therapy that inhibits MEK proteins. Some trials also combine it with other drugs like lapatinib, ipilimumab, nivolumab, or hydroxychloroquine.
  • How is dabrafenib mesylate administered to patients? Dabrafenib mesylate is given orally, usually twice daily. The exact dosage and schedule may vary between trials and may be adjusted based on how patients respond to treatment.
  • What are some of the main goals of these clinical trials? The main goals include determining the safety and effectiveness of dabrafenib-based treatments, evaluating progression-free survival, overall survival, tumor response rates, and assessing side effects. Some trials also aim to identify biomarkers that may predict treatment response.
  • Are there any unique dosing strategies being tested with dabrafenib? Yes, one trial is comparing continuous dosing of dabrafenib and trametinib to an intermittent dosing schedule to see if this affects treatment efficacy and side effects.

Ongoing Clinical Trials on Dabrafenib Mesylate

  • Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Hungary The Netherlands +1

  • Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +4

  • Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +2

Glossary

  • BRAF: A gene that provides instructions for making a protein involved in cell signaling and growth. Mutations in this gene are found in some cancers.
  • MEK: A protein involved in cell signaling pathways that regulate cell growth and survival. MEK inhibitors are used in some cancer treatments.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without the disease getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Adverse events: Unexpected medical problems that happen during treatment with a drug or other therapy.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that may signal an abnormal process, condition, or disease.
  • Circulating tumor DNA (ctDNA): Fragments of DNA from cancer cells that can be found circulating in the blood.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.

References

  1. https://clinicaltrials.gov/study/NCT04439292
  2. https://clinicaltrials.gov/study/NCT02281760
  3. https://clinicaltrials.gov/study/NCT01902173
  4. https://clinicaltrials.gov/study/NCT02224781
  5. https://clinicaltrials.gov/study/NCT01947023
  6. https://clinicaltrials.gov/study/NCT03919071
  7. https://clinicaltrials.gov/study/NCT02196181
  8. https://clinicaltrials.gov/study/NCT04557956